Title
Priorities to reduce the burden of stroke in Latin American countries
Date Issued
01 July 2019
Access level
metadata only access
Resource Type
review
Author(s)
Ouriques Martins S.C.
Sacks C.
Hacke W.
Brainin M.
de Assis Figueiredo F.
Marques Pontes-Neto O.
Lavados Germain P.M.
Marinho M.F.
Hoppe Wiegering A.
Vaca McGhie D.
Cruz-Flores S.
Ameriso S.F.
Camargo Villareal W.M.
Durán J.C.
Fogolin Passos J.E.
Gomes Nogueira R.
Freitas de Carvalho J.J.
Sampaio Silva G.
Cabral Moro C.H.
Oliveira-Filho J.
Gagliardi R.
Gomes de Sousa E.D.
Fagundes Soares F.
de Pinho Campos K.
Piza Teixeira P.F.
Gonçalves I.P.
Santos Carquin I.R.
Muñoz Collazos M.
Pérez Romero G.E.
Maldonado Figueredo J.I.
Barboza M.A.
Celis López M.
Góngora-Rivera F.
Cantú-Brito C.
Novarro-Escudero N.
Velázquez Blanco M.
Arbo Oze de Morvil C.A.
Olmedo Bareiro A.B.
Meza Rojas G.
Flores A.
Hancco-Saavedra J.A.
Pérez Jimenez V.
Rodriguez Kadota L.
Crosa R.
Mora Cuervo D.L.
de Souza A.C.
Carbonera L.A.
Álvarez Guzmán T.F.
Maldonado N.
Cabral N.L.
Anderson C.
Lindsay P.
Hennis A.
Feigin V.L.
Publisher(s)
Lancet Publishing Group
Abstract
The large and increasing burden of stroke in Latin American countries, and the need to meet the UN and WHO requirements for reducing the burden from non-communicable disorders (including stroke), brought together stroke experts and representatives of the Ministries of Health of 13 Latin American countries for the 1st Latin American Stroke Ministerial meeting in Gramado, Brazil, to discuss the problem and identify ways of cooperating to reduce the burden of stroke in the region. Discussions were focused on the regional and country-specific activities associated with stroke prevention and treatment, including public stroke awareness, prevention strategies, delivery and organisation of care, clinical practice gaps, and unmet needs. The meeting culminated with the adoption of the special Gramado Declaration, signed by all Ministerial officials who attended the meeting. With agreed priorities for stroke prevention, treatment, and research, an opportunity now exists to translate this Declaration into an action plan to reduce the burden of stroke.
Start page
674
End page
683
Volume
18
Issue
7
Language
English
OCDE Knowledge area
Sistema cardiaco, Sistema cardiovascular
Neurología clínica
Scopus EID
2-s2.0-85063019456
PubMed ID
Source
The Lancet Neurology
ISSN of the container
14744422
Sponsor(s)
VLF reports that Stroke Riskometer app is copyrighted by Auckland University of Technology, Auckland, New Zealand. PMLG reports grants, personal fees, and non-financial support from Bayer; grants from Population Health Research Institute, The George Institute for Global Health, and from Comisión Nacional de Investigación Científica y Tecnológica (FONIS programme); non-financial support from Boehringer Ingelheim; grants and non-financial support from Clinica Alemana; and honoraria for the development of Chilean national clinical guidelines in Intracerebral Haemorrhage. SCOM reports grants and personal fees from Boehringer Ingelheim; and personal fees from Medtronic, Bayer, Pfizer, outside the submitted work. OMPN reports grants from the Brazilian National Council of Scientific and Technological Development, during the conduct of this study. CA reports grants from the National Health and Medical Research Council of Australia and from Takeda; and personal fees from Takeda, Boehringer Ingelheim, and Amgen, outside the submitted work. SC-F reports personal fees from Novo Nordisk and Duke University, outside the submitted work. ACdeS reports personal fees from Boehringer, outside the submitted work. RGN reports non-financial support from Stryker Neurovascular as DAWN trial Principal Investigator and Trevo Registry Steering Committee member; personal and consultancy fees from Trevo-2 trial; personal fees from Phenox, Neuravi, Anaconda, Genentech, Biogen, Prolong Pharmaceuticals, and Medtronic; serves on the Physician Advisory Board for Allm Inc, Prolong Pharmaceuticals, Viz-Al, and Corindus Vascular; holds stock options in Viz-Al and Corindus Vascular Robotics; he reports personal fees from Medtronic as part of the SWIFT Trial Steering Committee and Star Trial Angiogiografic Core Lab; non-financial support from Medtronic as SWIFT-prime Trial Steering Committe member, Penumbra as 3D Separator Trial Executive Committee member, Neuravi as ENDOLOW Trial Principal Investigator, EXCELLENT Registry Principal Investigator and ARISE-2 trial Steering Committee member, Brainomix and Philips, for research software use, and Sensome for research device use; and reports personal fees from IschemaView and Philips as speaker, outside the submitted work. CSP, WH, MB, FAF, MFM, AHW, DVMG, SCF, SFA, WMCV, JCD, JEFP, JJFC, GSS, CHCM, JOF, RG, EDGS, FFS, KPC, PFPT, IPG, IRSC, MMC, GEPR, JIMF, MAB, MACL, FGR, CCB, NNE, MAVB, CAAOM, ABOB, GMR, AF, JAHS, VPJ, CAA, LRK, RC, DLMC, LAC, TFAG, NM, NLC, PL, and AH declare no competing interests.
Sources of information:
Directorio de Producción Científica
Scopus